{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-23-066311","form_type":"8-K","ticker":"MRKR","cik":"0001094038","company_name":"Marker Therapeutics, Inc.","filed_at":"2023-05-31T23:59:59+00:00","discovered_at":"2026-05-14T18:03:37.923030+00:00","generated_at":"2026-06-14T10:10:50.574644+00:00","sec_items":["7.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Marker Therapeutics reports pre-clinical data showing MT-601 kills CD19 CAR T refractory lymphoma cells","bullets":["In vitro, MT-601 completely inhibited growth of lymphoma cells resistant to CD19 CAR T therapy after 3 weeks.","Initial CAR T administration eliminated 98% of lymphoma cells; resistant population emerged; MT-601 overcame resistance.","MT-601 targets six antigens (including WT-1) vs. five in earlier TACTAL study, potentially offering more durable responses.","FDA cleared IND for MT-601; Phase 1 trial in relapsed non-Hodgkin lymphoma initiated Q1 2023."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-23-066311","json":"https://secwatch.observer/filing/0001104659-23-066311.json","markdown":"https://secwatch.observer/filing/0001104659-23-066311.md","text":"https://secwatch.observer/filing/0001104659-23-066311.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1094038/000110465923066311/0001104659-23-066311-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1094038/000110465923066311/tm2317378d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-14T10:10:50.574644+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}